Litigation Details for Ferring Pharmaceuticals Inc. v. Lupin Inc. (D. Del. 2019)
✉ Email this page to a colleague
Ferring Pharmaceuticals Inc. v. Lupin Inc. (D. Del. 2019)
| Docket | ⤷ Start Trial | Date Filed | 2019-05-16 |
| Court | District Court, D. Delaware | Date Terminated | 2021-07-12 |
| Cause | 35:183 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | Defendant | Referred To | |
| Parties | FERRING PHARMACEUTICALS INC. | ||
| Patents | 10,624,879; 9,827,231 | ||
| Attorneys | Kenneth Mueller | ||
| Firms | Phillips, Goldman, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Ferring Pharmaceuticals Inc. v. Lupin Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Ferring Pharmaceuticals Inc. v. Lupin Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-05-16 | External link to document | |||
| 2019-05-16 | 1 | Complaint | States Patent Number 9,827,231 prior to the expiration date of United States Patent Number 9,827,231 and…of United States Patent Number 9,827,231 (“the ’231 patent”) and United States Patent Number 9,669,110…United States Patent Number 9,827,231 will infringe one or more claims of United States Patent Number 9,…declaration that the claims of United States Patent Number 9,827,231 are valid and enforceable; b. …before the expiration of United States Patent Number 9,827,231 was an act of infringement under 35 U. | External link to document |
| 2019-05-16 | 108 | Notice of Service | Supplemental Infringement Contentions for U.S. Patent Numbers 9,827,231 and 10,624,879 filed by Ferring B.V., …2019 12 July 2021 1:19-cv-00913 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-05-16 | 121 | Notice of Service | Supplemental Infringement Contentions for U.S. Patent Numbers 9,827,231 and 10,624,879 and Ferring's Supplemental…2019 12 July 2021 1:19-cv-00913 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-05-16 | 137 | Notice of Service | Supplemental Infringement Contentions for U.S. Patent Nos. 9,827,231 and 10,624,879 and (2) Plaintiffs' Second…2019 12 July 2021 1:19-cv-00913 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-05-16 | 228 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,827,231; US 9,669,110; US…2019 12 July 2021 1:19-cv-00913 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-05-16 | 3 | ANDA Form | 4/4/2019. Date of Expiration of Patent: 6/23/2034 (as to US 9,827,231).Thirty Month Stay Deadline: 10/…10/4/2021 (as to US 9,827,231). (ceg) (Entered: 05/16/2019) 16 May 2019 PACER Document … Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …2019 12 July 2021 1:19-cv-00913 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Ferring Pharmaceuticals Inc. v. Lupin Inc. (1:19-cv-00913): Litigation Summary, Claim Scope, and Generic Entry Risk Assessment
More… ↓
